Net Income

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A new patent for reactivated carbon technology offers a circular solution to destroy "forever chemicals," promising a reliable path for U.S. water safety.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

New data shows flat 2026 raises for healthcare workers and a strategic pay gap, while AI's promised workforce revolution is still waiting in the wings.

With a $140M war chest, Empower Semiconductor expands to Silicon Valley and Munich, betting its vertical power tech can solve the energy crisis facing AI.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

With a critical $1.74M lifeline, Northstar Clean Technologies is racing to prove its shingle recycling tech can be a profitable circular economy champion.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.